US FDA’s Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication

Detalles Bibliográficos
Autores principales: Echols, Roger M, Nagata, Tsutae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366820/
https://www.ncbi.nlm.nih.gov/pubmed/34398951
http://dx.doi.org/10.1093/cid/ciab010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366820/
https://www.ncbi.nlm.nih.gov/pubmed/34398951
http://dx.doi.org/10.1093/cid/ciab010

Ejemplares similares